News & Updates

Show Multimedia Only

Deferiprone on par with deferoxamine for kids with rare anaemias

17 Dec 2021 by

In a subgroup analysis of the phase IV FIRST trial presented at ASH 2021, the oral iron chelator deferiprone was comparable to the infusion-administered deferoxamine in terms of efficacy and safety in iron-overloaded children receiving chronic transfusion therapy for sickle cell disease (SCD) and other anaemias.

Deferiprone on par with deferoxamine for kids with rare anaemias

17 Dec 2021

Remote management during chemotherapy fails to reduce ED visits, hospitalization

17 Dec 2021 by

A remote, proactive, and telephone-based management of toxicities in outpatients during adjuvant or neoadjuvant chemotherapy for early-stage breast cancer does not lead to fewer visits to the emergency department (ED) or hospital admissions, a study has shown.

Remote management during chemotherapy fails to reduce ED visits, hospitalization

17 Dec 2021

Apixaban outdoes rivaroxaban at preventing VTE, bleeding in adults

17 Dec 2021

Patients with venous thromboembolism (VTE) who are new users of apixaban are less likely to experience recurrent VTE and bleeding than new users of rivaroxaban, a study has shown.

Apixaban outdoes rivaroxaban at preventing VTE, bleeding in adults

17 Dec 2021

No benefit from adding interferon beta-1a to remdesivir in COVID-19

16 Dec 2021 by

Adding interferon beta-1a to remdesivir did not hasten time to recovery among adults hospitalized with COVID-19, according to results of the phase III ACTT*-3 trial.

No benefit from adding interferon beta-1a to remdesivir in COVID-19

16 Dec 2021

Certain IBD meds tied to excess risk of COVID-19 hospitalization

16 Dec 2021 by

While there are no differences in COVID-19-related outcomes in patients with inflammatory bowel disease (IBD) between those in remission vs those who are not, being on medications such as corticosteroids and aminosalicylates may put them at higher risk of hospitalization, suggest studies presented at AIBD 2021.

Certain IBD meds tied to excess risk of COVID-19 hospitalization

16 Dec 2021

Dabigatran or warfarin: Choice does not matter in GIRAF

16 Dec 2021 by

The choice of oral anticoagulant does not appear to influence the outcome in terms of preserving cognitive function in older patients with atrial fibrillation (AF), the GIRAF* study has shown.

Dabigatran or warfarin: Choice does not matter in GIRAF

16 Dec 2021

Ustekinumab yields high remission in Crohn’s disease, even for fistulizing disease

15 Dec 2021 by

Treatment with the anti-interleukin (IL)-12/-23 monoclonal antibody ustekinumab yields a high rate of clinical remission in patients with moderate-to-severe Crohn’s disease (CD) in the real-world setting, according to a study presented at AIBD 2021.

Ustekinumab yields high remission in Crohn’s disease, even for fistulizing disease

15 Dec 2021

Entecavir prevents HBV reactivation in individuals on DAA for HCV/HBV dual infection

15 Dec 2021

For patients undergoing direct acting antiviral (DAA) therapy for hepatitis C virus (HCV)/hepatitis B virus (HBV) dual infection, cotreatment with entecavir helps avert reactivation of HBV, as shown in a study.

Entecavir prevents HBV reactivation in individuals on DAA for HCV/HBV dual infection

15 Dec 2021

Study offers clues on which patients may safely stop HBV therapy

15 Dec 2021 by

Think twice before withdrawing HBV treatment. Not all patients can safely discontinue nucleos(t)ide analogue (NA) therapy as shown in the retrospective RETRACT-B study of patients from Europe, North America, and Asia.

Study offers clues on which patients may safely stop HBV therapy

15 Dec 2021

DOACs tied to lower risk of delayed ICH than older blood thinning meds

14 Dec 2021 by

Patients on older antiplatelet or anticoagulant agents who sustain head trauma may be at an increased risk of delayed post-traumatic intracranial haemorrhage (ICH) than those on direct oral anticoagulants (DOACs), according to a retrospective study presented at RSNA 2021.

DOACs tied to lower risk of delayed ICH than older blood thinning meds

14 Dec 2021

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Deferiprone on par with deferoxamine for kids with rare anaemias

Deferiprone on par with deferoxamine for kids with rare anaemias

Remote management during chemotherapy fails to reduce ED visits, hospitalization

Remote management during chemotherapy fails to reduce ED visits, hospitalization

Apixaban outdoes rivaroxaban at preventing VTE, bleeding in adults

Apixaban outdoes rivaroxaban at preventing VTE, bleeding in adults

No benefit from adding interferon beta-1a to remdesivir in COVID-19

No benefit from adding interferon beta-1a to remdesivir in COVID-19

Certain IBD meds tied to excess risk of COVID-19 hospitalization

Certain IBD meds tied to excess risk of COVID-19 hospitalization

Dabigatran or warfarin: Choice does not matter in GIRAF

Dabigatran or warfarin: Choice does not matter in GIRAF

Ustekinumab yields high remission in Crohn’s disease, even for fistulizing disease

Ustekinumab yields high remission in Crohn’s disease, even for fistulizing disease

Entecavir prevents HBV reactivation in individuals on DAA for HCV/HBV dual infection

Entecavir prevents HBV reactivation in individuals on DAA for HCV/HBV dual infection

Study offers clues on which patients may safely stop HBV therapy

Study offers clues on which patients may safely stop HBV therapy

DOACs tied to lower risk of delayed ICH than older blood thinning meds

DOACs tied to lower risk of delayed ICH than older blood thinning meds